151 related articles for article (PubMed ID: 25571620)
1. Three new agents added to the arsenal to fight MRSA.
Strain J
S D Med; 2014 Dec; 67(12):513-4. PubMed ID: 25571620
[No Abstract] [Full Text] [Related]
2. Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab.
Hussar DA; Nguyen A
J Am Pharm Assoc (2003); 2014; 54(6):658-62. PubMed ID: 25379985
[No Abstract] [Full Text] [Related]
3. New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.
Crotty MP; Krekel T; Burnham CA; Ritchie DJ
J Clin Microbiol; 2016 Sep; 54(9):2225-32. PubMed ID: 26962092
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial development in the era of emerging resistance.
Sorlozano A; Carrasco C; Cabeza J; Villegas E; Gutierrez J
Mini Rev Med Chem; 2009 Jul; 9(8):938-55. PubMed ID: 19601889
[TBL] [Abstract][Full Text] [Related]
5. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
Roberts KD; Sulaiman RM; Rybak MJ
Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
[TBL] [Abstract][Full Text] [Related]
6. New drugs 2015, part 2.
Hussar DA
Nursing; 2015 Jul; 45(7):34-41; quiz 41-2. PubMed ID: 26083291
[No Abstract] [Full Text] [Related]
7. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
8. Antibiotics.
Dalal KS; Bridgeman MB
Nursing; 2017 Mar; 47(3):70. PubMed ID: 28225406
[No Abstract] [Full Text] [Related]
9. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.
Russo A; Concia E; Cristini F; De Rosa FG; Esposito S; Menichetti F; Petrosillo N; Tumbarello M; Venditti M; Viale P; Viscoli C; Bassetti M
Clin Microbiol Infect; 2016 Apr; 22 Suppl 2():S27-36. PubMed ID: 27125562
[TBL] [Abstract][Full Text] [Related]
10. First vanguard anti-MRSA agent approved.
Fox JL
Nat Biotechnol; 2014 Jul; 32(7):603. PubMed ID: 25004211
[No Abstract] [Full Text] [Related]
11. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
Belley A; Lalonde Seguin D; Arhin F; Moeck G
Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327
[TBL] [Abstract][Full Text] [Related]
12. New Gram Positive Agents to Treat Acute Bacterial Skin and Skin Structure Infections.
Li R; Nailor MD
Conn Med; 2016 Mar; 80(3):175-80. PubMed ID: 27169303
[TBL] [Abstract][Full Text] [Related]
13. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.
Rybak JM; Marx K; Martin CA
Pharmacotherapy; 2014 Nov; 34(11):1198-208. PubMed ID: 25266820
[TBL] [Abstract][Full Text] [Related]
14. Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, β-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017-2019.
Sader HS; Streit JM; Mendes RE
Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115195. PubMed ID: 32977116
[TBL] [Abstract][Full Text] [Related]
15. New antimicrobial agents for methicillin-resistant Staphylococcus aureus.
Kollef MH
Crit Care Resusc; 2009 Dec; 11(4):282-6. PubMed ID: 20001879
[TBL] [Abstract][Full Text] [Related]
16. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
Van Bambeke F
Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of tedizolid against methicillin-resistant Staphylococcus aureus and Peptostreptococcus anaerobius in thigh mixed-infection mouse model.
Yamagishi Y; Mikamo H; Kato H; Nishiyama N; Asai N; Koizumi Y; Sakanashi D; Suematsu H; Matsuura K; Hagihara M
J Infect Chemother; 2017 Jun; 23(6):368-373. PubMed ID: 28343752
[TBL] [Abstract][Full Text] [Related]
18. Glycopeptides--important treatment option for methicillin-resistant Staphylococcus aureus.
Arora S; Arora U
Indian J Med Microbiol; 2011; 29(3):313-4. PubMed ID: 21860119
[No Abstract] [Full Text] [Related]
19. Telavancin.
Corey GR; Stryjewski ME; Weyenberg W; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2009 Dec; 8(12):929-30. PubMed ID: 19949399
[No Abstract] [Full Text] [Related]
20. Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.
Loffler CA; Macdougall C
Expert Rev Anti Infect Ther; 2007 Dec; 5(6):961-81. PubMed ID: 18039081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
